Status:
COMPLETED
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.
Lead Sponsor:
AstraZeneca
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine how well tolerated and safe AZD8566 is when given over 10 days, at different dose levels. This study will also determine how AZD8566 is distributed around the...
Eligibility Criteria
Inclusion
- Provision of written informed consent.
- Clinically normal physical findings and laboratory values as judged by the investigator with normal ECG
- Females who are permanently or surgically sterile or postmenopausal and males.
Exclusion
- Intake of medicine (except Hormone Replacement Therapy or occasional paracetamol) within 3 weeks before first administration of study drug
- History of any convulsions or seizures
- History of infection or at risk of infection due to recent surgery or trauma
- History or presence of conditions known to interfere with the absorption, distribution, metabolism and excretion of the study drug
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00844103
Start Date
January 1 2009
End Date
April 1 2009
Last Update
April 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Macclesfield, Cheshire, United Kingdom